CIK 0001980845 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
enGene Therapeutics Inc.
Sign in to watch- Ticker
- ENGN
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Oct 31
- Incorporated
- Canada (Federal Level)
- Entity type
- operating
- Phone
- (514) 332-4888
- Business address
- 4868 RUE LEVY, SUITE 220, SAINT-LAURENT, Quebec, Canada
- Former names
- enGene Holdings Inc.
Securities
- ENGN Common Stock Nasdaq
- ENGNW Warrants Nasdaq
- Open-market buys, last 90 days
- $10,051
- in 1 filing
- Open-market sales, last 90 days
- $0
- in 0 filings
Net +$10,051. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-07-08 | Astley-Sparke Philip Director | Grant or award · Stock Option (Right to Buy) | +45,000 | 45,000 | ||
| 2025-07-08 | Heffernan Michael Thomas Director | Grant or award · Stock Option (Right to Buy) | +45,000 | 45,000 | ||
| 2025-07-08 | Grossman William Director | Grant or award · Stock Option (Right to Buy) | +45,000 | 45,000 | ||
| 2025-07-08 | Buck Jill Chief Development Officer | Grant or award · Stock Option (Right to Buy) | +100,000 | 100,000 | ||
| 2025-06-16 | Zoth Lota S. Director | Grant or award · Stock Option (Right to Buy) | +22,500 | 22,500 | ||
| 2025-06-16 | Pott Amy Chief Global Comm. Ofc. | Grant or award · Stock Option (Right to Buy) | +400,000 | 400,000 | ||
| 2025-06-16 | Joustra Wouter Director | Grant or award · Stock Option (Right to Buy) | +22,500 | 22,500 | ||
| 2025-06-16 | HASTINGS PAUL J Director | Grant or award · Stock Option (Right to Buy) | +22,500 | 22,500 | ||
| 2025-06-16 | Glickman Richard M Director | Grant or award · Stock Option (Right to Buy) | +22,500 | 22,500 | ||
| 2025-06-16 | BRUNK GERALD A Director | Grant or award · Stock Option (Right to Buy) | +22,500 | 22,500 | ||
| 2025-06-16 | Bos Jasper Director | Grant or award · Stock Option (Right to Buy) | +22,500 | 22,500 | ||
| 2025-01-29 | Pruthi Raj Som Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +280,000 | 280,000 | ||
| 2025-01-29 | Nichols Alexander Julian Chief Strategy & Ops. Ofc | Grant or award · Stock Option (Right to Buy) | +250,000 | 250,000 | ||
| 2025-01-29 | Giguere Lee Chief Legal Ofc. and Corp Secy | Grant or award · Stock Option (Right to Buy) | +250,000 | 250,000 | ||
| 2025-01-29 | Daws D. Ryan Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +280,000 | 280,000 | ||
| 2025-01-29 | CHEUNG ANTHONY TZEYEW Chief Scientific Officer | Grant or award · Stock Option (Right to Buy) | +250,000 | 250,000 | ||
| 2025-01-29 | Cooper Ronald Harold Wilfred CEO & President | Grant or award · Stock Option (Right to Buy) | +850,000 | 850,000 | ||
| 2024-10-30 | Forbion Growth Opportunities Fund I Cooperatief U.A. 10% owner | Purchase | +561,797 | $8.90 | $5.0M | 3,032,430 |
| 2024-10-21 | CHEUNG ANTHONY TZEYEW Chief Scientific Officer | Grant or award · Stock Option (Right to Buy) | +100,000 | 100,000 | ||
| 2024-10-21 | Connolly Joan Chief Technology Officer | Grant or award · Stock Option (Right to Buy) | +210,000 | 210,000 |
Page 2 of 6 · 120 trades